Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation

Molecular Human Reproduction

Volumn 21, Issue 1, 2015, Pages 105-114

  Forbes, Karen ^a,b   Shah, Vinit K ^a,b   Siddals, Kirk ^c   Martin Gibson, J ^c   Aplin, John D ^a,b   Westwood, M ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Glycosylation; HMG CoA reductase; IGF; Proliferation; Trophoblast

Indexed keywords

1 DEOXYMANNONOJIRIMYCIN; CASTANOSPERMINE; CERIVASTATIN; FARNESYL DIPHOSPHATE; GLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LECTIN; PHYTOHEMAGGLUTININ; PRAVASTATIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TUNICAMYCIN; PYRIDINE DERIVATIVE; SOMATOMEDIN C;

ARTICLE; CELL LYSATE; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTROPHOBLAST; EXPLANT; FEMALE; FIRST TRIMESTER PREGNANCY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; PLACENTA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN GLYCOSYLATION; TISSUE CULTURE; TROPHOBLAST; WESTERN BLOTTING; DRUG EFFECTS; METABOLISM; PREGNANCY; SIGNAL TRANSDUCTION;

PHASEOLUS VULGARIS;

FEMALE; GLYCOSYLATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN-LIKE GROWTH FACTOR I; PLACENTA; PRAVASTATIN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PYRIDINES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84922444959     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gau093     Document Type: Article

References (66)

1. Aplin JD. Implantation, trophoblast differentiation and haemochorial placentation: mechanistic evidence in vivo and in vitro. J Cell Sci 1991; 99(Pt 4):681-692.
2. Aplin J. Maternal influences on placental development. Semin Cell Dev Biol 2000; 11: 115-125.
3. Aplin JD. Developmental cell biology of human villous trophoblast: current research problems. Int J Dev Biol 2010; 54: 323-329.
4. Aplin JD, Jones CJ. Fucose, placental evolution and the glycocode. Glycobiology 2012; 22: 470-478.
5. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
6. Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, Gilbert JS. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013; 61: 1103-1110.
7. Cantoni S, Cavallini C, Bianchi F, Bonavita F, Vaccari V, Olivi E, Frascari I, Tassinari R, Valente S, Lionetti V et al. Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. Pharmacol Res 2011; 65: 275-284.
8. Carroll KK, Guthrie N, Ravi K. Dolichol: function, metabolism, and accumulation in human tissues. Biochem Cell Biol 1992; 70: 382-384.
9. Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121: 349-353.
10. Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 2002; 417: 945-948.
11. Constancia M, Angiolini E, Sandovici I, Smith P, Smith R, Kelsey G, Dean W, Ferguson-Smith A, Sibley CP, Reik W et al. Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci USA 2005; 102: 19219-19224.
12. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 2008; 68: 3803-3809.
13. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GD, Saade GR. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010; 116: 114-120.
14. Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology 1997; 7: 625-633.
15. Dricu A, Kanter L, Wang M, Nilsson G, Hjertman M, Wejde J, Larsson O. Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Glycobiology 1999; 9: 571-579.
16. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38: 90-96.
17. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 39-47.
18. Forbes K, Westwood M. The IGF axis and placental function. a mini review. Horm Res 2008;69:129-137.
19. Forbes K, Westwood M. Maternal growth factor regulation of human placental development and fetal growth. J Endocrinol 2010; 207: 1-16.
20. Forbes K, Hurst LM, Aplin JD, Westwood M, Gibson JM. Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable. J Cell Mol Med 2008a; 12: 2295-2296.
21. Forbes K, Westwood M, Baker PN, Aplin JD. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am J Physiol Cell Physiol 2008b; 294:C1313-C1C22.
22. Forbes K, West G, Garside R, Aplin JD, Westwood M. The protein-tyrosine phosphatase, SRC homology-2 domain containing protein tyrosine phosphatase-2, is a crucial mediator of exogenous insulin-like growth factor signaling to human trophoblast. Endocrinology 2009; 150: 4744-4754.
23. Forbes K, Skinner L, Aplin JD, Westwood M. The tyrosine phosphatase SHP-1 negatively regulates cytotrophoblast proliferation in first-trimester human placenta by modulating EGFR activation. Cell Mol Life Sci 2012; 23: 4029-4040.
24. Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, Hankins GD, Saade GR, Costantine MM. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011; 205:366 e1-5.
25. Fuhrmann U, Bause E, Legler G, Ploegh H. Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides. Nature 1984; 307: 755-758.
26. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol 2009; 82: 126-131.
27. Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol 2013;101-102:161-7.
28. Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J, Larsson O. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des 2000; 15: 67-72.
29. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother 2012; 46: 1419-1424.
30. Gonzalez JM, Pedroni SM, Girardi G. Statins prevent cervical remodeling, myometrial contractions and preterm labor through a mechanism that involves hemoxygenase-1 and complement inhibition. Mol Hum Reprod 2014; 20: 579-589.
31. Heffner LJ. Advanced maternal age-how old is too old? N Engl J Med 2004; 351:1927-1929.
32. ISRCTN I. A proof of principle, double-blind, randomised placebo-controlled, multicentre trial of pravastatin to ameliorate early onset pre-eclampsia. Current Controlled Trials, Identifier ISRCTN23410175, London, 2009.
33. Itkonen HM, Mills IG. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One 2013; 8: e65016.
34. Jansson T, Powell TL. Human placental transport in altered fetal growth: does the placenta function as a nutrient sensor?-a review. Placenta 2006; 27: 91-97.
35. Jones CJ, Aplin JD. Glycosylation at the fetomaternal interface: does the glycocode play a critical role in implantation? Glycoconj J 2009; 26:359-366.
36. Jones CJ, Skidmore JA, Aplin JD. Placental glycosylation in a cama (camel-llama cross) and its relevance to successful hybridisation. Mol Phylogenet Evol 2008; 49: 1030-1035.
37. Jones CJ, Carter AM, Aplin JD, Enders AC. Glycosylation at the fetomaternal interface in hemomonochorial placentae from five widely separated species of mammal: is there evidence for convergent evolution? Cells Tissues Organs 2007;185:269-284.
38. Kenis I, Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, Pomeranz M, Lishner M. Simvastatin has deleterious effects on human first trimester placental explants. Hum Reprod 2005; 20: 2866-2872.
39. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW et al. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One 2012; 7: e33322.
40. Kruis T, Klammt J, Galli-Tsinopoulou A, Wallborn T, Schlicke M, Muller E, Kratzsch J, Korner A, Odeh R, Kiess W et al. Heterozygous mutation within a kinase-conserved motif of the insulin-like growth factor I receptor causes intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 2010; 95: 1137-1142.
41. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108: 1451-1455.
42. Kusters DM, Hassani Lahsinoui H, van de Post JA, Wiegman A, Wijburg FA, Kastelein JJ, Hutten BA. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012; 10: 363-378.
43. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 2012; 72: 773-788.
44. Liao Y, Zhao H, Ogai A, Kato H, Asakura M, Kim J, Asanuma H, Minamino T, Takashima S, Kitakaze M. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008; 31: 335-344.
45. Masnikosa R, Baricevic I, Jones DR, Nedic O. Characterisation of insulin-like growth factor receptors and insulin receptors in the human placenta using lectin affinity methods. Growth Horm IGF Res 2006; 16: 174-184.
46. McDowell W, Schwarz RT. Dissecting glycoprotein biosynthesis by the use of specific inhibitors. Biochimie 1988; 70: 1535-1549.
47. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol 2013; 209:373 e1-5.
48. Odiari EA, Mulla MJ, Sfakianaki AK, Paidas MJ, Stanwood NL, Gariepy A, Brosens JJ, Chamley LW, Abrahams VM. Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Hum Reprod 2012; 27: 2933-2940.
49. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
50. Schumacher U, Thielke E, Adam E. A dot blot technique for the analysis of interactions of lectins with glycosaminoglycans. Histochem J 1992; 24: 453-455.
51. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 2008; 372: 356-361.
52. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
53. Sibley CP, Coan PM, Ferguson-Smith AC, Dean W, Hughes J, Smith P, Reik W, Burton GJ, Fowden AL, Constancia M. Placental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci USA 2004; 101: 8204-8208.
54. Siddals KW, Marshman E, Westwood M, Gibson JM. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action bymevalonicaciddepletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 2004; 279: 38353-9.
55. Siddals KW, Allen J, Sinha S, Canfield AE, Kalra PA, Gibson JM. Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization. J Biol Chem 2011; 286: 16623-16630.
56. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011; 58: 716-724.
57. Soderquist AM, Carpenter G. Glycosylation of the epidermal growth factor receptor in A-431 cells. The contribution of carbohydrate to receptor function. J Biol Chem 1984;259:12586-12594.
58. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001; 5: 378-387.
59. Tartakover-Matalon S, Cherepnin N, Kuchuk M, Drucker L, Kenis I, Fishman A, Pomeranz M, Lishner M. Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod 2007; 22: 1161-1167.
60. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF, Breuning MH, Romijn JA, Karperien M, Wit JM. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab 2006; 91: 3062-3070.
61. Wang XQ, Sun P, O'Gorman M, Tai T, Paller AS. Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppression [correction of suppression] of activation. Glycobiology 2001; 11: 515-522.
62. Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, Johns TG, Beth AH, Staros JV. Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry 2005; 44: 14920-14931.
63. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004; 27: 1047-1053.
64. Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Merlob P, Cuppers-Maarschalkerweerd B, Vial T, Stephens S, Clementi M, De Santis M et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013; 120: 463-471.
65. Zarek J, DeGorter MK, Lubetsky A, Kim RB, Laskin CA, Berger H, Koren G. The transfer of pravastatin in the dually perfused human placenta. Placenta 2013; 34: 719-721.
66. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, Dimitroulakos J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 2010; 29: 4682-4692.